PAD Profile : Continuous Glucose Monitoring - Congenital hyperinsulinism

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Continuous Glucose Monitoring - Congenital hyperinsulinism

PAD Profile : Continuous Glucose Monitoring - Congenital hyperinsulinism

Keywords :

real time, rtCGM, gastrostomy

Brand Names Include :

Freestyle Libre 3, Dexcom One, Dexcom 6, Dexcom 7, Medtronic Guardian

Traffic Light Status

Status 1 of 1.

Status :

Red

Formulations :

Device

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

ICB

BlueTeq

Comments :

Patients must be under the care of a national CHI centre (see PAD for details).

Documents :

Type

Document

Review Date

Policy Statement

CGM for patients with Congenital Hyperinsulism and gastrostomy pump in situ Sep23.pdf

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date

Committee Name

Narrative

04 October 2023

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves real time continuous glucose monitoring (RTCGM) devices for patients with congenital hyperinsulinism (CHI) who are under the care of one of the 3 nationally commissioned centres:

· Great Ormond Street Hospital for Children NHS Foundation Trust

· Manchester University NHS Foundation Trust

· Alder Hey Children’s NHS Foundation Trust

AND who require overnight continuous enteral glucose delivery via a gastrostomy feed pump. rtCGM acts as an additional alert in case of gastrostomy feed pump failure.

RTCGM will be given a RED traffic light status for this indication.

Associated BNF Codes

No BNF codes returned.